-
'Where is she?' The desperate search for Venezuela's missing
-
Former Barca teen star Fati seals permanent Monaco switch
-
No business as usual after shock World Cup exit, say German FA
-
German rail regulator backs Italian firm in competition spat
-
Pope appeals to Catholic traditionalists to avoid schism
-
Ancelotti shows Brazil his worth at World Cup but concerns remain
-
US Supreme Court upholds transgender sports bans
-
Stocks rise, yen at 40-year low against dollar
-
US Supreme Court rejects Trump bid to restrict birthright citizenship
-
Australia hold West Indies to 125-7 in World Cup semi-final
-
Serena set for remarkable Wimbledon return, Swiatek survives scare
-
Defending champ Swiatek survives scare to reach Wimbledon second round
-
Africa EV firm Spiro accused of torturing Uganda employees
-
US Supreme Court upholds state bans on transgender athletes in school
-
PSG's Portugal forward Ramos signs five-year AC Milan deal
-
Tourists soldier on in Rome despite heatwave
-
Inflation slows in top eurozone economies as ECB ponders next move
-
Record number of 'new millionaires' in 2025, says UBS
-
Starmer boosts budget to modernise UK military before exit
-
UN calls for food, shelter to help Venezuela quake survivors
-
Stocks mostly higher, yen stays near 40-year low against dollar
-
Merz faces mockery over praise of Germany's World Cup team
-
Data centres emitting more CO2 than thought: study
-
Ride-share group BlaBlaCar taps AI for 20-country expansion
-
Over 1 million migrants apply for Spain's mass regularisation
-
Escaping heat, forgetting war: Kyiv locals hit the beach
-
Germany questions footballing identity after fresh World Cup failure
-
Thousands march to demand illegal migrants leave South Africa
-
MEXC Lists Ondo's Tokenized Strategy Preferred Stock on Spot Market
-
Serena set for remarkable Wimbledon return
-
Stocks climb, yen stays near 40-year low against dollar
-
Outgoing UK PM Starmer announces 'record' defence spending
-
Swim star Marchand limps out of French nationals as Europeans loom
-
Paralluelo joins Barca women's departures
-
UN says transport infrastructure must adapt to climate
-
Police hunt for Monaco bomb suspect after Ukrainian-born businessman wounded
-
Sommer, Acerbi, Darmian, De Vrij leave Inter Milan
-
Sommer, Acerbi, Darmian leave Inter Milan
-
Germany's labour market dilemma: rising unemployment despite vacancies
-
'Waiting like torture': Turks despair as Schengen visa delays mount
-
Skating allows Russian, Belarussians to return as neutrals
-
Venezuela rescuers in final push to find survivors as families mourn
-
Russian double Olympic figure skating champion Dmitriev dies aged 58
-
Over 1 million migrants apply for Spain's mass regularisation: PM
-
S. Africa deploys police as anti-migrant protests loom
-
Thousands from Philippine sect protest pro-Duterte senator's graft case
-
Monaco parcel bomb blast wounds Ukrainian oligarch
-
South Africa repatriations top 25,000 ahead of anti-immigrant ultimatum
-
Sweden face France's attacking firepower at the World Cup
-
Taiwan raids tech firms in China AI chip smuggling probe
US House votes for life-changing $35 insulin price cap
US lawmakers voted Thursday on a bill limiting the cost of insulin to $35 a month, a transformative curb for millions of diabetics who pay hundreds of dollars for the life-sustaining hormone.
Drug pricing has vexed politicians for years in the United States, which has the highest annual health expenditure of any industrialized country, at around $11,000 per capita.
Insulin costs the 7.4 million American adults who use it to manage their diabetes eight times as much as in other wealthy nations, according to a 2020 study commissioned by the Health and Human Services Department.
"This is a kitchen table issue: are people going to be able to pay their bills? And it is, for us, a step in the direction of the (government) being able to negotiate for lower drug prices beyond insulin," House Speaker Nancy Pelosi told reporters.
The legislation passed the House of Representatives by 232 votes to 193, with a handful of Republicans crossing the aisle to join the Democrats, and now advances to the upper chamber of Congress, the US Senate.
It would require private health insurance companies to set prices for a month's supply of insulin at no more than $35, or 25 percent of a plan's negotiated price, whichever is lower, starting in 2023 for some patients and 2024 for all.
The cap was a provision in President Joe Biden's "Build Back Better" social welfare bill that was torpedoed by Democratic infighting in Congress late last year.
Biden brought the issue back into the spotlight during his State of the Union address on March 1, reinvigorating calls for action on pricing from diabetes advocates.
The effort is being seen as the only way for Democrats to show they're capable of acting on sky-high prescription drug prices before November's midterm elections.
- 'Costing a lot' -
The Senate is holding its own cross-party negotiations on driving down insulin costs by targeting the middlemen between health insurance companies and pharmacies.
And a separate Democrat-only bill from Georgia's Senator Raphael Warnock that would also cap the price at $35 is likely to be combined with the effort.
"I'm a pastor -- I'm on the ground -- and so I know that everybody knows somebody with diabetes," Warnock said in a video promoting his initiative.
Senate Majority Leader Chuck Schumer told reporters last week he believed a bipartisan bill had a good chance of passing when lawmakers return from a break at the end of April.
Research suggests that more than a quarter of Americans with type 1 diabetes have had to ration insulin they could not afford. Campaigners say the proportion went up to 50 percent during the pandemic.
It remains unclear if any legislation can gain the 10 Republican votes needed to advance in the Senate, but some opposition lawmakers have shown interest in an issue that affects voters across the board.
"I'd be for some kind of regulation where we can help. Too many people (are) paying thousands of dollars a month. I'm not big on regulating process, but that one's costing a lot of people a lot of money," Alabama Senator Tommy Tuberville told Axios.
Republicans on the powerful House Ways and Means Committee described the vote as "the largest expansion of federal command and control in Americans' private health insurance design" since the Affordable Care Act, the landmark 2010 regulatory overhaul and expansion of health care coverage.
"Democrats are reviving their socialist drug pricing scheme from their failed radical tax and spending spree," the committee's top Republican Kevin Brady said in a statement.
J.Bergmann--BTB